Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Q1 2025 earnings

Reported May 1, 2025 · After market close

Revenue$78.3MMiss by $20.8M
EPS-$0.64Beat by $0.05
Revenue estimate$99.1M
EPS estimate-$0.69

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$183.7M
EPS estimate-$1.43

Financials

Q1 2025

Income statement

See full
Revenue$78.3M+184%
Gross profit$73.1M—
Operating income-$26.3M+30.3%
Net income-$25.1M+29.7%
EPS (diluted)-$0.64+36.6%

Balance sheet

See full
Cash & equivalents$178.4M-7.9%
Total debt$72.4M+125%
Total equity$342.5M+24.4%
Total assets$500.8M+43.4%

Cash flow

See full
Operating cash flow-$20.7M+45.4%
CapEx$590.0K+239%
Free cash flow-$21.2M+44.0%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.12B+64.9%
Enterprise value$2.01B+79.2%
P/S9.1×-21.1×

Profitability

See full
Operating margin-46.7%-21.8pp
Net margin-44.9%-20.9pp
FCF margin-29%-13.8pp

Returns & leverage

See full
Return on equity-34%-11.1pp
Debt / equity0.2×+0.1×
Current ratio5.6×-2.4×

Segments

By segment

See full
Reportable Segment$78.3M+184%

FAQ

When did Tarsus Pharmaceuticals, Inc. report Q1 2025 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q1 2025 earnings on May 1, 2025 after market close.
What were Tarsus Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $78.3M and eps of $-0.64 for Q1 2025.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $99.1M by $20.8M. EPS beat the consensus estimate of $-0.69 by $0.05.
How did Tarsus Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 183.7% from $27.6M a year earlier and eps grew 36.6% from $-1.01.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001819790-25-000077) and the 10-Q periodic report (0001819790-25-000078) directly on SEC EDGAR. The filing index links above go to sec.gov.